Macrophage mal1 deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-γ-regulated genes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 6, 2011, Pages 1283-1290

  Babaev, Vladimir R ^a,b   Runner, Robert P ^a   Fan, Daping ^a   Ding, Lei ^a   Zhang, Youmin ^a   Tao, Huan ^a   Erbay, Ebru ^c   Görgün, Cem Z ^d   Fazio, Sergio ^a   Hotamisligil, Gökhan S ^d   Linton, MacRae F ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BILKENT UNIVERSITY   (Turkey)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CCR2; CD36; macrophages; PPAR

Indexed keywords

CARRIER PROTEIN; CD36 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL; FATTY ACID BINDING PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL COUNT; CONTROLLED STUDY; LIPID DIET; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; LIPIDS; MACROPHAGES; MICE; NEOPLASM PROTEINS; PPAR GAMMA; RECEPTORS, CCR2; RECEPTORS, LDL;

EID: 79957528361     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.225839     Document Type: Article

References (32)

1. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci. 2002;59: 1096-1116.
2. Furuhashi M, Hotamisligil G. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7:489-503. (Pubitemid 351767117)
3. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil G. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22:1686-1691.
4. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil G. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;110:1492-1498. (Pubitemid 39238029)
5. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001;7:699-705. (Pubitemid 32588026)
6. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil G. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity: macrophage expression of aP2 impacts peroxisome proliferator-activated receptor and I-B kinase activities. J Biol Chem. 2005;280:12888-12895.
7. Haunerland NH, Spener F. Fatty acid-binding proteins: insights from genetic manipulations. Progr Lipid Res. 2004;43:328-349. (Pubitemid 38952618)
8. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN-target genes in macrophages. Proc Natl Acad Sci USA. 2003;100: 6712-6717. (Pubitemid 36666645)
9. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism. 2005;1:107-119. (Pubitemid 43960591)
10. Babaev VR, Chew JD, Ding L, Davis S, Breyer MD, Breyer RM, Oates JA, Fazio S, Linton MF. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metabolism. 2008;8:492-501.
11. Liu H, Perlman H, Pagliari LJ, Pope RM. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages: role of Mcl-1, independent of nuclear factor (NF)-B, Bad, or caspase activation. J Exp Med. 2001;194:113-126.
12. Bronson SK, Smithies O. Altering mice by homologous recombination using embryonic stem cells. J Biol Chem. 1994;269:27155-27158. (Pubitemid 24346525)
13. Maeda K, Uysal KT, Makowski L, Gorgun CZ, Atsumi G, Parker RA, Bruning J, Hertzel AV, Bernlohr DA, Hotamisligil GS. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes. 2003;52:300-307. (Pubitemid 36173182)
14. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995;267:1034-1037.
15. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPAR-increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25: 1647-1653. (Pubitemid 41098935)
16. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res. 2006;47:2726-2737. (Pubitemid 44936086)
17. Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. J Biol Chem. 2000;275: 23807-23813. (Pubitemid 30624666)
18. Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF. Macrophage expression of peroxisome proliferator-activated receptor-reduces atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Circulation. 2007;116: 1404-1412. (Pubitemid 47417567)
19. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002;41:6640-6650. (Pubitemid 34547354)
20. Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008;118:2640-2650. (Pubitemid 351949791)
21. Helledie T, Antonius M, Sorensen RV, Hertzel AV, Bernlohr DA, lvraa S, Kristiansen K, Mandrup S. Lipid-binding proteins modulate liganddependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm. J Lipid Res. 2000;41:1740-1751.
22. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006;116:607-614. (Pubitemid 43326865)
23. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell. 2001;7:161-171. (Pubitemid 32162909)
24. Li Y, Gerbod-Giannone M-C, Seitz H, Cui D, Thorp E, Tall AR, Matsushima GK, Tabas I. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem. 2006;281:6707-6717. (Pubitemid 43847606)
25. Zhu X, Lee J-Y, Timmins JM, Brown JM, Boudyguina E, Mulya A, Gebre AK, Willingham MC, Hiltbold EM, Mishra N, Maeda N, Parks JS. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem. 2008;283:22930-22941.
26. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005;24:7435-7442. (Pubitemid 41637983)
27. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, Birnbaum MJ, Sessa WC. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metabolism. 2007;6:446-457. (Pubitemid 350163050)
28. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621. (Pubitemid 43209108)
29. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPAR activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabolism. 2007;6: 137-143. (Pubitemid 47189091)
30. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, Quehenberger O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor-. J Clin Invest. 2000;106:793-802.
31. Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1412-1418.
32. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447:959-965. (Pubitemid 46975747)